JUNSHI BIO

1877
14.1605.28% ( -0.790 )
Delay Closed: Nov 16, 16:08:11

Overview

JUNSHI BIO (1877)

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The...

Open
15.010
High
15.100
Low
14.000
Prev. Close
14.950
Volume
2.64M
Turnover
37.55M
Avg Price
14.248
Bid/Ask Ratio
15.79%
Amplitude
7.36%
52wk High
30.800
Volume Ratio
0.60
Turnover Ratio
1.01%
52wk Low
14.000
HK Mkt Cap
3.69B
Market CapHKD
14.54B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.448
EPSDynamic
-0.226
EPSStatic
--
BVPS
6.62
P/B
2.14
HK Shares
260.30M
Dividend YieldTTM
--
DividendTTM
--
Shares
1.03B
Min lot size
200
Currency
HKD

JUNSHI BIO Analyst Rating

View more

Forecast & Rating

Nov 3, 2026
Price forecast
HK$28.34100.12%
Forecast & RatingBuy
4analysts
  • Strong buy75.00%
  • Buy0.00%
  • Hold25.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Junshi Biosciences fell 4.48% to HK$14.28 in a spike-and-fade session: it opened at HK$15.01, tagged HK$15.10 in the morning, then slid to HK$14.00 before closing near the low on HK$37.4 million turnover, extending the weak tone after the stock set a fresh 52-week low of HK$14.00 in the prior session. Fundamentals cut against the tape: Q3 2026 revenue rose 37.21% year on year to HK$956.1 million and operating income jumped 230.21% to HK$172.3 million, yet the quarter still posted a HK$199.9 million net loss with EPS of -HK$0.2445, down 23.83%, versus Q2's HK$48.8 million net profit; the regular approval of toripalimab in urothelial cancer and first dosing of JS207 plus JS007 in a Phase 3 liver cancer trial did not lift the shares. At HK$14.28 the price sits below the MA20 of HK$15.81 and MA60 of HK$17.20, down 35.91% year to date and 53.64% from the HK$30.80 52-week high, just 2% above the low, with PB at 2.16x. Though CICC carries a Buy rating and revenue has grown above 37% for two straight quarters.

  2. Nov, 13

    Junshi Biosciences fell 5.02% to HK$14.95 on 13 Nov in a spike-and-fade session: it printed HK$15.65 at 09:36 BJ before sliding to HK$14.95 by 15:50 on 1.23 million shares. Phase 3 lung-cancer data showing toripalimab plus chemotherapy cut death risk 34%, together with regular China approval in urothelial cancer, failed to hold the stock up. Fundamentals are split: Q3 revenue rose 37.21% YoY to HK$956 million and operating profit jumped 230.21% to HK$172 million, yet the net loss was HK$200 million at a -20.9% margin versus a HK$49 million profit in Q2; PE stands at -33.41 and PB at 2.26. The shares are down 32.9% YTD, 51.46% below the 52-week high of HK$30.8 and only about 1% above the HK$14.8 low, trading under MA20 of HK$15.91 and MA60 of HK$17.29. While first patients have been dosed in the Phase 3 trials of JS207 plus JS007 in liver cancer and JS203 in lymphoma.

  3. Oct, 22

    Junshi Biosciences opened at HK$17.05, slid to an intraday low of HK$16.33 and closed at HK$16.73, down 2.73% from the prior close of HK$17.20, as an earlier peer rights issue kept Hong Kong small-cap biotech sentiment under pressure and left individual names diverging. The move contrasts with Q2 numbers: revenue of HK$1.12bn, up 53.1% yoy, and net profit of HK$48.77m, up 125.03%, with EPS turning positive at HK$0.0429 versus -HK$0.0227 in Q1 and a 4.35% net margin, though Q2 operating profit stayed negative at -HK$58.78m. The stock trades below its MA20 of HK$17.60 and MA60 of HK$18.14, is down 24.91% year-to-date, sits 45.68% below the 52-week high of HK$30.80 and 9.7% above the HK$15.25 low. BNP Paribas earlier added 204,800 shares at HK$17.96, above the current price, while full-day volume reached about 1.79m shares on a 0.69% turnover rate.

  4. Oct, 21

    Junshi Bio rose 3.74% to HK$17.20, opening flat at the prior close before grinding higher to an intraday peak of HK$17.45 at 11:35 BJ and easing back in the afternoon, on 1.877 million shares worth HK$32.3 million. The push came from the H1 turnaround: first-half revenue up 45% to RMB1.7 billion with net profit swinging to RMB25.5 million, while Q2 alone showed revenue of HK$1.12 billion (+53.1% yoy), net profit of HK$48.8 million (+125%) and EPS of HK$0.0429, alongside a partnership with Meijie Medical on multimodal drug-device combinations in oncology that earlier lifted the shares over 4% in one session. BNP Paribas added 204,800 shares at HK$17.96. Still, the price sits below its MA20 of 17.734 and MA60 of 18.178, 44.16% under the 52-week high of HK$30.80, with YTD down 22.8%, leaving a visible gap between improving fundamentals and price position.

  5. Oct, 7

    Junshi Biosciences spiked early then faded, sliding about 3.5% to HK$17.89 from HK$18.54 after touching an intraday low of HK$17.22 at 09:51 BJ and recovering from HK$17.69 in the afternoon, on roughly HK$9.8 million turnover and a 0.21% turnover rate. Interim net profit of RMB25.5 million on revenue of RMB1.7 billion, up 45% year on year, together with UBS noting most China biotech firms beat 1H26 sales expectations, drove the morning pop; a key A-share investor's disclosed stake-reduction plan and the termination of the 2026 A-share employee ownership scheme capped the rebound. Q2 revenue of HK$1.119 billion rose 53.15% and net profit of HK$48.7 million rose 125.04%, yet the price sits below MA20 of 17.982 and MA60 of 18.526, down 19.7% year to date and about 45% below the 52-week high of 32.62. While profitability has only just turned positive on a thin base, the intraday range reached roughly 7%.

News